In more detail, 78% of oligodendrogliomas (WHO grade II) showed focal GAL-immunoreactivity (<1–10% of tumor cells) and 89% contained areas of diffuse GAL staining (Figure 6A). This evidence concerns the gene GAL and neoplasm.